BREAST CANCER

Neoadjuvant ado-trastuzumab emtansine demonstrated promising complete pathological response in patients with hormone receptor-positive and HER2-positive early stage breast cancer

Massimo Cristofanilli, MD, Jefferson University Physician, professor, director, Breast Care Center, Jefferson University Hospital, discusses the next steps following the PALOMA3 trial, which was a randomized, placebo-controlled phase III study examining palbociclib plus fulvestrant in pre- and post-menopausal patients with ER-positive breast cancer.

Triple-Negative Breast Cancer

Triple-Negative Breast Cancer

Erika P. Hamilton, MD, associate director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase 1b study examining ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine and trastuzumab in the third-line setting and treatment of HER2-positive metastatic breast cancer.

Inhibition of the activin receptor-like kinase 1 (ALK1) protein may prevent metastasis of breast cancer, according to a study published in Cancer Research.

BRCA and other mutations occurred in more than 10% of estrogen-receptor–positive/HER2-negative invasive breast cancers in a cohort of women younger than 50 years of age, according to a report at the 2015 ASCO Annual Meeting.

Homologous repair deficiency or a high HRD score identified triple-negative breast cancers that had an increased likelihood of pathologic complete response to chemotherapy, according to a study reported at the 2015 ASCO Annual Meeting.

Adding palbociclib to standard fulvestrant more than doubled progression-free survival in pretreated patients who have HR-positive, HER2-negative breast cancer.